Risk of mTOR inhibitors induced severe pneumonitis in cancer patients: a meta-analysis of randomized controlled trials

被引：4

作者：

Zhang, Xi ^{[1
]}

Ran, Yu-ge ^{[1
]}

Wang, Kun-jie ^{[2
]}

机构：

[1] Hebei Univ, Affiliated Hosp, Dept Radiat Oncol, Baoding 071000, Peoples R China

[2] Hebei Univ, Affiliated Hosp, Dept Med Oncol, Baoding 071000, Peoples R China

来源：

FUTURE ONCOLOGY | 2016年 / 12卷 / 12期

关键词：

cancer; meta-analysis; mTOR inhibitors; pneumonitis; RENAL-CELL CARCINOMA; PHASE-III TRIAL; DRUG-RELATED PNEUMONITIS; MAMMALIAN TARGET; DOUBLE-BLIND; BREAST-CANCER; NONINFECTIOUS PNEUMONITIS; NEUROENDOCRINE TUMORS; INTERFERON-ALPHA; RAPAMYCIN MTOR;

D O I：

10.2217/fon-2016-0020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: A meta-analysis of randomized controlled trials was performed to determine the overall risk of noninfectious severe pneumonitis associated with mTOR inhibitors (mTORi) in cancer patients. Materials & methods: PubMed, EMBASE and oncology conference proceedings were searched for relevant studies. Results: A total of 8377 patients from 16 randomized controlled trials were included. The incidence of severe pneumonitis associated with mTORi was 1.7% (95% CI: 1.1-2.5%). The use of mTORi significantly increased the risk of severe pneumonitis compared with controls (odds ratio: 3.36; 95% CI: 2.20-5.12). The analysis was stratified for drug types, tumor types, controlled therapy and mTORi-based regimens, but no significant differences in odds ratios were observed. Conclusion: mTORi significantly increase the risk of severe pneumonitis in cancer patients.

引用

页码：1529 / 1539

页数：11

共 50 条

[1] Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma [J].

Albiges, L. ;

Chamming's, F. ;

Duclos, B. ;

Stern, M. ;

Motzer, R. J. ;

Ravaud, A. ;

Camus, P. .

ANNALS OF ONCOLOGY, 2012, 23 (08) :1943-1953

[2] Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial [J].

Andre, Fabrice ;

O'Regan, Ruth ;

Ozguroglu, Mustafa ;

Toi, Masakazu ;

Xu, Binghe ;

Jerusalem, Guy ;

Masuda, Norikazu ;

Wilks, Sharon ;

Arena, Francis ;

Isaacs, Claudine ;

Yap, Yoon-Sim ;

Papai, Zsuzsanna ;

Lang, Istvan ;

Armstrong, Anne ;

Lerzo, Guillermo ;

White, Michelle ;

Shen, Kunwei ;

Litton, Jennifer ;

Chen, David ;

Zhang, Yufen ;

Ali, Shyanne ;

Taran, Tetiana ;

Gianni, Luca .

LANCET ONCOLOGY, 2014, 15 (06) :580-591

[3] Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study [J].

Bachelot, Thomas ;

Bourgier, Celine ;

Cropet, Claire ;

Ray-Coquard, Isabelle ;

Ferrero, Jean-Marc ;

Freyer, Gilles ;

Abadie-Lacourtoisie, Sophie ;

Eymard, Jean-Christophe ;

Debled, Marc ;

Spaeth, Dominique ;

Legouffe, Eric ;

Allouache, Djelila ;

El Kouri, Claude ;

Pujade-Lauraine, Eric .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (22) :2718-2724

[4] Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer [J].

Baselga, Jose ;

Campone, Mario ;

Piccart, Martine ;

Burris, Howard A., III ;

Rugo, Hope S. ;

Sahmoud, Tarek ;

Noguchi, Shinzaburo ;

Gnant, Michael ;

Pritchard, Kathleen I. ;

Lebrun, Fabienne ;

Beck, J. Thaddeus ;

Ito, Yoshinori ;

Yardley, Denise ;

Deleu, Ines ;

Perez, Alejandra ;

Bachelot, Thomas ;

Vittori, Luc ;

Xu, Zhiying ;

Mukhopadhyay, Pabak ;

Lebwohl, David ;

Hortobagyi, Gabriel N. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (06) :520-529

[5] Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer [J].

Baselga, Jose ;

Semiglazov, Vladimir ;

van Dam, Peter ;

Manikhas, Alexey ;

Bellet, Meritxell ;

Mayordomo, Jose ;

Campone, Mario ;

Kubista, Ernst ;

Greil, Richard ;

Bianchi, Giulia ;

Steinseifer, Jutta ;

Molloy, Betty ;

Tokaji, Erika ;

Gardner, Humphrey ;

Phillips, Penny ;

Stumm, Michael ;

Lane, Heidi A. ;

Dixon, J. Michael ;

Jonat, Walter ;

Rugo, Hope S. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) :2630-2637

[6] OPERATING CHARACTERISTICS OF A BANK CORRELATION TEST FOR PUBLICATION BIAS [J].

BEGG, CB ;

MAZUMDAR, M .

BIOMETRICS, 1994, 50 (04) :1088-1101

[7] Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features [J].

Bellmunt, J. ;

Szczylik, C. ;

Feingold, J. ;

Strahs, A. ;

Berkenblit, A. .

ANNALS OF ONCOLOGY, 2008, 19 (08) :1387-1392

[8] Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial [J].

Bissler, John J. ;

Kingswood, J. Christopher ;

Radzikowska, Elzbieta ;

Zonnenberg, Bernard A. ;

Frost, Michael ;

Belousova, Elena ;

Sauter, Matthias ;

Nonomura, Norio ;

Brakemeier, Susanne ;

de Vries, Petrus J. ;

Whittemore, Vicky H. ;

Chen, David ;

Sahmoud, Tarek ;

Shah, Gaurav ;

Lincy, Jeremie ;

Lebwohl, David ;

Budde, Klemens .

LANCET, 2013, 381 (9869) :817-824

[9] Temsirolimus in the treatment of mantle cell lymphoma: frequency and management of adverse effects [J].

Bouabdallah, Krimo ;

Ribrag, Vincent ;

Terriou, Louis ;

Soria, Jean-Charles ;

Delarue, Richard .

CURRENT OPINION IN ONCOLOGY, 2013, 25 :S1-S12

[10] Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer [J].

Chan, S .

BRITISH JOURNAL OF CANCER, 2004, 91 (08) :1420-1424

← 1 2 3 4 5 →